Literature DB >> 33397433

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers.

Qiao-Xuan Wang1,2, Chun-Hua Qu1,3, Yuan-Hong Gao1,2, Pei-Rong Ding1,4, Jing-Ping Yun1,3, Dan Xie5,6, Mu-Yan Cai7,8.   

Abstract

The development of programmed cell death-1 inhibitor (PD-1) has shed light on the treatment of tumors with deficiencies in DNA mismatch repair system or microsatellite instability (dMMR/MSI). However, predicting the subset in this group that will benefit from PD-1 blockade remains a challenge. In this study, we aimed to investigate the relationship between the degree of microsatellite instability and the responses to anti-PD-1 immunotherapy. 33 patients with colorectal adenocarcinoma who had a known MSI status and received anti-PD-1 immunotherapy were included. PCR results for MSI of the whole cohort were collected and treatment response was evaluated. Our data indicated that objective response rate (ORR) in instability-high group (instability loci ≥ 3) was significantly higher than ORR in instability-intermediate group (13/16 versus 6/17, P = 0.008). Besides, patients in instability-high group had significant longer progression-free survival (log-rank test, P = 0.004), and a significant increase in T lymphocyte infiltration and cytolytic activity in tumors. Future study might implement the intensity of microsatellite instability for more delicate selection for anti-PD-1 therapy in patient with dMMR/MSI-H tumors.

Entities:  

Keywords:  Anti-PD-1 immunotherapy; Colorectal cancer; dMMR/MSI-H

Year:  2021        PMID: 33397433     DOI: 10.1186/s40164-020-00193-z

Source DB:  PubMed          Journal:  Exp Hematol Oncol        ISSN: 2162-3619


  6 in total

Review 1.  Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy.

Authors:  Ahmed Halima; Winston Vuong; Timothy A Chan
Journal:  J Clin Invest       Date:  2022-06-15       Impact factor: 19.456

2.  Programmed death-ligand 1 and mammalian target of rapamycin signaling pathway in locally advanced rectal cancer.

Authors:  Yanru Feng; Jialin Luo; Peng Liu; Yuan Zhu; Guoping Cheng; Linfeng Zheng; Luying Liu
Journal:  Discov Oncol       Date:  2022-02-14

Review 3.  Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Xingcheng Yang; Ling Ma; Xiaoying Zhang; Liang Huang; Jia Wei
Journal:  Exp Hematol Oncol       Date:  2022-03-02

4.  Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis.

Authors:  Alejandro Olivares-Hernández; Edel Del Barco Morillo; Carmen Parra Pérez; José Pablo Miramontes-González; Luis Figuero-Pérez; Teresa Martín-Gómez; Roberto Escala-Cornejo; Lorena Bellido Hernández; Rogelio González Sarmiento; Juan Jesús Cruz-Hernández; María Dolores Ludeña de la Cruz
Journal:  Biomedicines       Date:  2022-02-02

5.  Microtube Array Membrane Hollow Fiber Assay (MTAM-HFA)-An Accurate and Rapid Potential Companion Diagnostic and Pharmacological Interrogation Solution for Cancer Immunotherapy (PD-1/PD-L1).

Authors:  Wan-Ting Huang; Tsao Yun; Chee-Ho Chew; Amanda Chen; Po-Li Wei; Kang-Yun Lee; Hsin-Lun Lee; Po-Hao Feng; Jeng-Fong Chiou; Ching-Mei Chen; Chien-Chung Chen
Journal:  Biomolecules       Date:  2022-03-22

Review 6.  Recent advances in Lynch syndrome.

Authors:  Xi Li; Guodong Liu; Wei Wu
Journal:  Exp Hematol Oncol       Date:  2021-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.